Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · RECURSION PHARMACEUTICALS, INC. (RXRX)

Recursion Q3 revenue rises to $18.6 million; net loss narrows to $119.0 million

Positive Impact 3 of 5 earnings Written later

Recursion reported third-quarter 2026 results, with total revenue of $18.6 million, up from $5.2 million a year earlier, and a net loss of $119.0 million, down from $162.3 million. The company said its cash runway now extends into 2029, including proceeds from an October 2026 offering, and that Fred Hassan was appointed Chair of the Board effective October 31, 2026.

Key points

  • Total revenue was $18.6 million for Q3 2026 versus $5.2 million for Q3 2025, driven mainly by a $10.0 million Sanofi milestone
  • Net loss was $119.0 million, or $0.22 per share, versus $162.3 million, or $0.36 per share, a year earlier
  • Cash, cash equivalents and restricted cash were $561.5 million at September 30, 2026; pro forma about $748.7 million including about $187.2 million in offering proceeds
  • Fred Hassan was appointed Chair of the Board effective October 31, 2026

The filing

CompanyRECURSION PHARMACEUTICALS, INC. (RXRX)
Form8-K, current report
Filed with the SECNov 2, 2026, 4:32 PM ET
Accession number0001601830-26-000144

Items reported: 2.02 Results of Operations5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.